基于药物遗传信息的阿扎西奥普林剂量量调整:临床实施的洞察力
Xando Díaz-Villamarín1, Emilio Fernández-Varón2, Michelle Carolina Rojas Romero1
1Instituto de Investigación Biosanitaria de Granada (Ibs.Granada), Granada, Spain.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 19, 2023
概括
根据提奥普林-S-甲基转移酶 (TPMT) 基因量身定制阿扎西奥普林剂量,可以减少中间代谢物的毒性和剂量调整. 这种个性化的方法可以改善患者的治疗结果,而不会影响阿扎西奥普林治疗的治疗疗效.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
- 免疫抑制疗法是一种免疫抑制疗法.
背景情况:
- 阿扎西奥普林是白血病,自身免疫性疾病和器官移植的重要免疫抑制剂.
- 提奥普林-S-甲基转移酶 (TPMT) 和努迪克斯酶15 (NUDT15) 的遗传变异对阿扎西奥普林的新陈代谢和反应有显著的影响.
- 目前的指导方针建议对TPMT中间体 (IM) 和低代谢剂 (PM) 进行剂量调整,以减轻毒性.
研究的目的:
- 通过TPMT基因定型指导,评估阿扎西奥普林剂量个性化的临床影响.
- 为了比较TPMT IM/PM和正常代谢器 (NM) 患者之间的阿扎西奥普林毒性,疗效和剂量调整.
- 评估NUDT15 rs116855232在TPMT引导的治疗策略中的阿扎西奥普林反应中的作用.
主要方法:
- 对TPMT变种 (rs1800462,rs1800460,rs1142345,rs75543815) 和NUDT15 rs116855232.2) 的基因造型研究
- 对阿扎西奥普林毒性,疗效和剂量调整的比较,根据TPMT代谢器状态分层的患者 (NM,IM,PM).
- 基于药物遗传特征的治疗开始和随访剂量修改的分析.
主要成果:
- 在TPMT IM患者 (TPMT*1/*2, *1/*3A, *1/*3C基因型) 的剂量减少导致与TPMT NM (*1/*1基因型) 相比,毒性事件显著降低.
- 在随访期间,TPMT IM患者需要更少的阿扎西奥普林剂量调整,没有观察到治疗疗效的差异.
- 这项研究支持存在其他影响阿扎西奥普林毒性的遗传因素,超出了TPMT和NUDT15.
结论:
- 基于TPMT基因型的阿扎西奥普林剂量个性化有效降低毒性,简化治疗管理.
- 以TPMT为指导的剂量量定制是优化不同患者群体中阿扎西奥普林治疗的宝贵策略.
- 对阿扎西奥普林反应的其他遗传决定因素的进一步研究是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Renal Failure: Dose Adjustments
97
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
97
Drug Dosage Regimen: Overview
3.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


